Download PDF
Dtsch Med Wochenschr 2012; 137(40): 1998-2001
DOI: 10.1055/s-0032-1305272
Endokrinologie und Diabetologie | Commentary
Diabetologie, Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Diabetes und Niere

Diabetes and the kidneys
B. Hohenstein
1   Medizinische Klinik 3, Bereich Nephrologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
,
C. Hugo
1   Medizinische Klinik 3, Bereich Nephrologie, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden
› Author Affiliations
Further Information

Publication History

Publication Date:
28 September 2012 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

diabetische Nephropathie - antidiabetische Therapie - Blutdrucksenkung - duale Renin-Angiotensin-Hemmung

Keywords

diabetic nephropathy - glucose control - blood pressure control - dual renin-angiotensin inhibition
 

  • Literatur

  • 1 Bailey CJ, Gross JL, Pieters A et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin. Lancet 2010; 375: 2223-2233
    CrossrefPubMedGoogle Scholar
  • 2 Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes. Ann Intern Med 2009; 151: 11-20, W3-4
    CrossrefPubMedGoogle Scholar
  • 3 Bonegio R, Susztak K. Notch signaling in diabetic nephropathy. Exp Cell Res 2012; 318: 986-992
    CrossrefPubMedGoogle Scholar
  • 4 de Boer IH, Sun W, Cleary PA et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-2376
    CrossrefPubMedGoogle Scholar
  • 5 Fioretto P, Steffes MW, Sutherland DE et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339: 69-75
    CrossrefPubMedGoogle Scholar
  • 6 Fiorina P, Folli F, Zerbini G et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14: 2150-2158
    CrossrefPubMedGoogle Scholar
  • 7 Godel M, Hartleben B, Herbach N et al. Role of Mtor in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest 2011; 121: 2197-2209
    CrossrefPubMedGoogle Scholar
  • 8 Haller H, Ito S, Izzo Jr JL et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907-917
    CrossrefPubMedGoogle Scholar
  • 9 Ismail-Beigi F, Craven TE, O’Connor PJ et al. Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int 2012; 81: 586-594
    CrossrefPubMedGoogle Scholar
  • 10 Levey AS, Cattran D, Friedman A et al. Proteinuria as a surrogate outcome in Ckd: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226
    CrossrefPubMedGoogle Scholar
  • 11 Ludwig B, Ludwig S, Steffen A et al. Islet versus pancreas transplantation in type 1 diabetes: competitive or complementary?. Curr Diab Rep 2010; 10: 506-511
    CrossrefPubMedGoogle Scholar
  • 12 Ludwig B, Rotem A, Schmid J et al. Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A 2012; 109: 5022-5027
    CrossrefPubMedGoogle Scholar
  • 13 Parving HH, Brenner BM, McMurray JJ et al. Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (Altitude). J Renin Angiotensin Aldosterone Syst 2012; Feb 14. [Epub ahead of print]
    PubMedGoogle Scholar
  • 14 Patel A, MacMahon S, Chalmers J et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the Advance Trial). Lancet 2007; 370: 829-840
    CrossrefPubMedGoogle Scholar
  • 15 Pergola PE, Raskin P, Toto RD et al. Bardoxolone methyl and kidney function in Ckd with type 2 diabetes. N Engl J Med 2011; 365; 327-336
    PubMedGoogle Scholar
  • 16 Pohl MA, Blumenthal S, Cordonnier DJ et al. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 3027-3037
    CrossrefPubMedGoogle Scholar
  • 17 Schmieder RE, Klingbeil AU, Fleischmann EH et al. Additional antiproteinuric effect of ultrahigh dose candesartan. J Am Soc Nephrol 2005; 16: 3038-3045
    CrossrefPubMedGoogle Scholar
  • 18 Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
    CrossrefPubMedGoogle Scholar
  • 19 Wittmann S, Daniel C, Stief A et al. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat. Transplantation 2009; 87: 1290-1299
    CrossrefPubMedGoogle Scholar
  • 20 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
    CrossrefPubMedGoogle Scholar